Relationship between the frequency of influenza vaccination and cell-mediated immunity
Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-med...
Saved in:
Published in | Journal of immunological methods Vol. 458; pp. 58 - 62 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.07.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-mediated immunity (CMI) with respect to the number of influenza vaccine doses. In particular, the influenza vaccine was administered to 21 adults during the 2015–2016 season. IFN-γ production induced by the influenza vaccine antigens [A (H1N1), A (H3N2), B (Yamagata lineage), and B (Victoria lineage)] increased after the first dose of vaccination in 11, 10, 10, and 11 subjects, respectively. In 5 of 10 (H1N1), 4 of 10 (H3N2), 3 of 9 (Yamagata lineage), and 3 of 8 (Victoria lineage) subjects who did not exhibit an increase in IFN-γ production after the first dose, CMI was enhanced after the second dose. The production of IFN-γ increased after the first or second dose of the vaccine in 16, 14, 13, and 14 of the 21 subjects, respectively. The results of this study showed that two doses of the influenza vaccine effectively enhance CMI in subjects with primary vaccine failure.
•Cell-mediated immunity was assessed after one and two vaccine doses.•A second vaccine dose enhanced CMI in subjects with primary vaccine failure.•In subjects with CMI after one dose, a second dose did not act as a booster.•There was significant correlation between the HAI antibody titer and NT.•There was no significant correlation between CMI and the HAI antibody titer and NT. |
---|---|
AbstractList | Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-mediated immunity (CMI) with respect to the number of influenza vaccine doses. In particular, the influenza vaccine was administered to 21 adults during the 2015–2016 season. IFN-γ production induced by the influenza vaccine antigens [A (H1N1), A (H3N2), B (Yamagata lineage), and B (Victoria lineage)] increased after the first dose of vaccination in 11, 10, 10, and 11 subjects, respectively. In 5 of 10 (H1N1), 4 of 10 (H3N2), 3 of 9 (Yamagata lineage), and 3 of 8 (Victoria lineage) subjects who did not exhibit an increase in IFN-γ production after the first dose, CMI was enhanced after the second dose. The production of IFN-γ increased after the first or second dose of the vaccine in 16, 14, 13, and 14 of the 21 subjects, respectively. The results of this study showed that two doses of the influenza vaccine effectively enhance CMI in subjects with primary vaccine failure. Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-mediated immunity (CMI) with respect to the number of influenza vaccine doses. In particular, the influenza vaccine was administered to 21 adults during the 2015-2016 season. IFN-γ production induced by the influenza vaccine antigens [A (H1N1), A (H3N2), B (Yamagata lineage), and B (Victoria lineage)] increased after the first dose of vaccination in 11, 10, 10, and 11 subjects, respectively. In 5 of 10 (H1N1), 4 of 10 (H3N2), 3 of 9 (Yamagata lineage), and 3 of 8 (Victoria lineage) subjects who did not exhibit an increase in IFN-γ production after the first dose, CMI was enhanced after the second dose. The production of IFN-γ increased after the first or second dose of the vaccine in 16, 14, 13, and 14 of the 21 subjects, respectively. The results of this study showed that two doses of the influenza vaccine effectively enhance CMI in subjects with primary vaccine failure.Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-mediated immunity (CMI) with respect to the number of influenza vaccine doses. In particular, the influenza vaccine was administered to 21 adults during the 2015-2016 season. IFN-γ production induced by the influenza vaccine antigens [A (H1N1), A (H3N2), B (Yamagata lineage), and B (Victoria lineage)] increased after the first dose of vaccination in 11, 10, 10, and 11 subjects, respectively. In 5 of 10 (H1N1), 4 of 10 (H3N2), 3 of 9 (Yamagata lineage), and 3 of 8 (Victoria lineage) subjects who did not exhibit an increase in IFN-γ production after the first dose, CMI was enhanced after the second dose. The production of IFN-γ increased after the first or second dose of the vaccine in 16, 14, 13, and 14 of the 21 subjects, respectively. The results of this study showed that two doses of the influenza vaccine effectively enhance CMI in subjects with primary vaccine failure. Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-mediated immunity (CMI) with respect to the number of influenza vaccine doses. In particular, the influenza vaccine was administered to 21 adults during the 2015–2016 season. IFN-γ production induced by the influenza vaccine antigens [A (H1N1), A (H3N2), B (Yamagata lineage), and B (Victoria lineage)] increased after the first dose of vaccination in 11, 10, 10, and 11 subjects, respectively. In 5 of 10 (H1N1), 4 of 10 (H3N2), 3 of 9 (Yamagata lineage), and 3 of 8 (Victoria lineage) subjects who did not exhibit an increase in IFN-γ production after the first dose, CMI was enhanced after the second dose. The production of IFN-γ increased after the first or second dose of the vaccine in 16, 14, 13, and 14 of the 21 subjects, respectively. The results of this study showed that two doses of the influenza vaccine effectively enhance CMI in subjects with primary vaccine failure. •Cell-mediated immunity was assessed after one and two vaccine doses.•A second vaccine dose enhanced CMI in subjects with primary vaccine failure.•In subjects with CMI after one dose, a second dose did not act as a booster.•There was significant correlation between the HAI antibody titer and NT.•There was no significant correlation between CMI and the HAI antibody titer and NT. |
Author | Otani, Naruhito Yoshida, Natsuko Honjo, Kenta Okuno, Toshiomi Ichiki, Kaoru Nakajima, Kazuhiko Takesue, Yoshio Ueda, Takashi Kawata, Sayo Shima, Masayuki |
Author_xml | – sequence: 1 givenname: Naruhito surname: Otani fullname: Otani, Naruhito email: naruhito@fa2.so-net.ne.jp organization: Department of Public Health, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan – sequence: 2 givenname: Masayuki orcidid: 0000-0002-8783-7879 surname: Shima fullname: Shima, Masayuki organization: Department of Public Health, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan – sequence: 3 givenname: Takashi surname: Ueda fullname: Ueda, Takashi organization: Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan – sequence: 4 givenname: Kaoru surname: Ichiki fullname: Ichiki, Kaoru organization: Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan – sequence: 5 givenname: Kazuhiko surname: Nakajima fullname: Nakajima, Kazuhiko organization: Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan – sequence: 6 givenname: Yoshio surname: Takesue fullname: Takesue, Yoshio organization: Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan – sequence: 7 givenname: Kenta surname: Honjo fullname: Honjo, Kenta organization: Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa 768-0061, Japan – sequence: 8 givenname: Natsuko surname: Yoshida fullname: Yoshida, Natsuko organization: Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa 768-0061, Japan – sequence: 9 givenname: Sayo surname: Kawata fullname: Kawata, Sayo organization: Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa 768-0061, Japan – sequence: 10 givenname: Toshiomi surname: Okuno fullname: Okuno, Toshiomi organization: Department of Microbiology, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29684427$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1r3DAQhkVJaTZpf0Avxcde7I5kfdj0VEK_IFAoba9ClkZEiy1vJW3C9tdXm00uPaQnMfA8w-h9L8hZXCMS8ppCR4HKd9tuG5aOAR064B3A8Ixs6KBYq0YQZ2QDwFhLlRjPyUXOWwCgIOEFOWejHDhnakN-fcfZlLDGfBN2zYTlDjE25QYbn_D3HqM9NKtvQvRzHf6Y5tZYG-K90pjoGovz3C7oginomrAs-xjK4SV57s2c8dXDe0l-fvr44-pLe_3t89erD9et5YKVVsh-mhgqKxkbECekzo9CUMVHJ5CPXvUSRymdn3rlvKMw9jjYHpXkAML1l-Ttae8urfXaXPQS8vEkE3HdZ82o6GXPKIX_o9BXqm7lFX3zgO6n-jW9S2Ex6aAfY6uAOgE2rTkn9NqGcp9JSSbMmoI-FqS3uhakjwVp4LoWVE36j_m4_Cnn_cnBmuRtwKSzDbWZGnpCW7RbwxP2XxCrqG4 |
CitedBy_id | crossref_primary_10_3390_vaccines12060584 crossref_primary_10_3390_v13061137 crossref_primary_10_1111_1348_0421_12687 |
Cites_doi | 10.1128/CVI.00397-07 10.1002/jmv.22273 10.1016/j.vaccine.2009.01.136 10.15585/mmwr.mm6430a3 10.1016/j.jim.2009.09.010 10.2169/internalmedicine.56.7533 10.1016/j.jim.2014.06.006 10.1056/NEJMcp1512870 10.1186/s12879-016-1978-0 10.1371/journal.ppat.0030151 10.1016/j.cellimm.2016.09.005 10.2807/1560-7917.ES.2016.21.11.30168 |
ContentType | Journal Article |
Copyright | 2018 Elsevier B.V. Copyright © 2018 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2018 Elsevier B.V. – notice: Copyright © 2018 Elsevier B.V. All rights reserved. |
DBID | AAYXX CITATION NPM 7X8 7S9 L.6 |
DOI | 10.1016/j.jim.2018.04.008 |
DatabaseName | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | AGRICOLA MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1872-7905 |
EndPage | 62 |
ExternalDocumentID | 29684427 10_1016_j_jim_2018_04_008 S0022175918300309 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .55 .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXUO ABEFU ABFNM ABFRF ABGSF ABJNI ABMAC ABUDA ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFFNX AFKWA AFTJW AFXIZ AGEKW AGHFR AGRDE AGUBO AGYEJ AHHHB AHPSJ AI. AIEXJ AIKHN AITUG AJBFU AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CJTIS CNWQP CS3 D-I DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMG HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LUGTX M41 MO0 N9A O-L O9- OAUVE OHT OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SIN SPCBC SSI SSU SSZ T5K UAP VH1 WUQ X7M XFK XPP Y6R ZGI ZMT ~G- AAHBH AATTM AAXKI AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION SSH NPM 7X8 7S9 L.6 |
ID | FETCH-LOGICAL-c452t-563bb2e7c6228eebe1df9551749d5e49f736e966dfb37dfd1093e8c3e764005d3 |
IEDL.DBID | .~1 |
ISSN | 0022-1759 1872-7905 |
IngestDate | Thu Jul 10 23:13:29 EDT 2025 Fri Jul 11 11:44:56 EDT 2025 Wed Feb 19 02:35:51 EST 2025 Thu Apr 24 23:05:42 EDT 2025 Tue Jul 01 03:53:58 EDT 2025 Fri Feb 23 02:31:07 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Cell-mediated immunity NT IR one dose Hemagglutination inhibition Neutralizing antibody GMT two doses HAI IFN-γ IIV Influenza vaccine CMI |
Language | English |
License | Copyright © 2018 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c452t-563bb2e7c6228eebe1df9551749d5e49f736e966dfb37dfd1093e8c3e764005d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-8783-7879 |
PMID | 29684427 |
PQID | 2031030054 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_2153632110 proquest_miscellaneous_2031030054 pubmed_primary_29684427 crossref_citationtrail_10_1016_j_jim_2018_04_008 crossref_primary_10_1016_j_jim_2018_04_008 elsevier_sciencedirect_doi_10_1016_j_jim_2018_04_008 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-07-01 |
PublicationDateYYYYMMDD | 2018-07-01 |
PublicationDate_xml | – month: 07 year: 2018 text: 2018-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Journal of immunological methods |
PublicationTitleAlternate | J Immunol Methods |
PublicationYear | 2018 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (bb0025) 1997 Otani, Shima, Nakajima, Takesue, Okuno (bb0070) 2014; 411 Forrest, Pride, Dunning, Capeding, Chotpitayasunondh, Tam, Rappaport, Eldridge, Gruber (bb0030) 2008; 15 National Institute of Infectious Diseases (NIID) (bb0060) 2017 Treanor (bb0085) 2016; 375 Ainai, Tamura, Suzuki, Ito, Asanuma, Tanimoto, Gomi, Manabe, Ishikawa, Okuno, Odagiri (bb0005) 2012; 84 INFLUENZA VACCINE “BIKEN” package insert, 26th ed. (Japanese). McElhaney, Ewen, Zhou, Kane, Xie, Hager, Barry, Kleppinger, Wang, Bleackley (bb0055) 2009; 27 Lowen, Mubareka, Steel, Palese (bb0050) 2007; 3 Tanabe, Nakamura, Arai, Yamasaki, Hirano, Kobayashi, Taguchi, Kaneko, Ito (bb0080) 2017; 56 Centers for Disease Control and Prevention (CDC) (bb0015) 2017 Otani, Shima, Ueda, Ichiki, Nakajima, Takesue, Okuno (bb0075) 2016; 310 Centers for Disease Control and Prevention (CDC) (bb0010) 2015 Grohskopf, Sokolow, Olson, Bresee, Broder, Karron (bb0035) 2015; 64 Iha, Kinjo, Parrott, Higa, Mori, Fujita (bb0040) 2016; 16 Chambers, Skowronski, Sabaiduc, Winter, Dickinson, De Serres, Gubbay, Drews, Martineau, Eshaghi, Krajden (bb0020) 2016; 21 Otani, Baba, Okuno (bb0065) 2009; 351 Otani (10.1016/j.jim.2018.04.008_bb0075) 2016; 310 Tanabe (10.1016/j.jim.2018.04.008_bb0080) 2017; 56 Treanor (10.1016/j.jim.2018.04.008_bb0085) 2016; 375 Iha (10.1016/j.jim.2018.04.008_bb0040) 2016; 16 Otani (10.1016/j.jim.2018.04.008_bb0065) 2009; 351 Ainai (10.1016/j.jim.2018.04.008_bb0005) 2012; 84 10.1016/j.jim.2018.04.008_bb0045 Chambers (10.1016/j.jim.2018.04.008_bb0020) 2016; 21 McElhaney (10.1016/j.jim.2018.04.008_bb0055) 2009; 27 European Agency for the Evaluation of Medicinal Products (EMEA) (10.1016/j.jim.2018.04.008_bb0025) 1997 Grohskopf (10.1016/j.jim.2018.04.008_bb0035) 2015; 64 Lowen (10.1016/j.jim.2018.04.008_bb0050) 2007; 3 National Institute of Infectious Diseases (NIID) (10.1016/j.jim.2018.04.008_bb0060) 2017 Centers for Disease Control and Prevention (CDC) (10.1016/j.jim.2018.04.008_bb0010) 2015 Otani (10.1016/j.jim.2018.04.008_bb0070) 2014; 411 Centers for Disease Control and Prevention (CDC) (10.1016/j.jim.2018.04.008_bb0015) 2017 Forrest (10.1016/j.jim.2018.04.008_bb0030) 2008; 15 |
References_xml | – year: 1997 ident: bb0025 article-title: Note for guidance on harmonization of requirements for influenza vaccines – volume: 16 start-page: 650 year: 2016 ident: bb0040 article-title: Comparative epidemiology of influenza A and B viral infection in a subtropical region: a 7-year surveillance in Okinawa, Japan publication-title: BMC Infect. Dis. – volume: 64 start-page: 818 year: 2015 end-page: 825 ident: bb0035 article-title: Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015–16 influenza season publication-title: MMWR Morb. Mortal. Wkly Rep. – volume: 21 year: 2016 ident: bb0020 article-title: Interim estimates of 2015/16 vaccine effectiveness against influenza A (H1N1) pdm09, Canada, February 2016 publication-title: Euro. Surveill. – volume: 310 start-page: 165 year: 2016 end-page: 169 ident: bb0075 article-title: Evaluation of influenza vaccine-immunogenicity in cell-mediated immunity publication-title: Cell. Immunol. – volume: 351 start-page: 71 year: 2009 end-page: 74 ident: bb0065 article-title: Interferon-gamma release assay: a simple method for detection of varicella-zoster virus-specific cell-mediated immunity publication-title: J. Immunol. Methods – volume: 3 start-page: 1470 year: 2007 end-page: 1476 ident: bb0050 article-title: Influenza virus transmission is dependent on relative humidity and temperature publication-title: PLoS Pathog. – year: 2017 ident: bb0060 article-title: Weekly reports of influenza virus isolation/detection, week 20/2016-week 3/2017 – volume: 56 start-page: 773 year: 2017 end-page: 779 ident: bb0080 article-title: The direct comparison of two interferon-gamma release assays in the tuberculosis screening of Japanese healthcare workers publication-title: Intern. Med. – volume: 27 start-page: 2418 year: 2009 end-page: 2425 ident: bb0055 article-title: Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults publication-title: Vaccine – volume: 15 start-page: 1042 year: 2008 end-page: 1053 ident: bb0030 article-title: Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children publication-title: Clin. Vaccine Immunol. – reference: INFLUENZA VACCINE “BIKEN” package insert, 26th ed. (Japanese). – year: 2017 ident: bb0015 article-title: Summary of the 2015–2016 influenza season – volume: 375 start-page: 1261 year: 2016 end-page: 1268 ident: bb0085 article-title: Clinical practice. Influenza vaccination publication-title: N. Engl. J. Med. – volume: 84 start-page: 336 year: 2012 end-page: 344 ident: bb0005 article-title: Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine publication-title: J. Med. Virol. – start-page: 187 year: 2015 end-page: 207 ident: bb0010 article-title: Influenza publication-title: Epidemiology and Prevention of Vaccine-Preventable Diseases – volume: 411 start-page: 50 year: 2014 end-page: 54 ident: bb0070 article-title: Development of a simplified and convenient assay for cell-mediated immunity to the mumps virus publication-title: J. Immunol. Methods – start-page: 187 year: 2015 ident: 10.1016/j.jim.2018.04.008_bb0010 article-title: Influenza – volume: 15 start-page: 1042 year: 2008 ident: 10.1016/j.jim.2018.04.008_bb0030 article-title: Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children publication-title: Clin. Vaccine Immunol. doi: 10.1128/CVI.00397-07 – volume: 84 start-page: 336 year: 2012 ident: 10.1016/j.jim.2018.04.008_bb0005 article-title: Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine publication-title: J. Med. Virol. doi: 10.1002/jmv.22273 – volume: 27 start-page: 2418 year: 2009 ident: 10.1016/j.jim.2018.04.008_bb0055 article-title: Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults publication-title: Vaccine doi: 10.1016/j.vaccine.2009.01.136 – volume: 64 start-page: 818 year: 2015 ident: 10.1016/j.jim.2018.04.008_bb0035 article-title: Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015–16 influenza season publication-title: MMWR Morb. Mortal. Wkly Rep. doi: 10.15585/mmwr.mm6430a3 – volume: 351 start-page: 71 year: 2009 ident: 10.1016/j.jim.2018.04.008_bb0065 article-title: Interferon-gamma release assay: a simple method for detection of varicella-zoster virus-specific cell-mediated immunity publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2009.09.010 – volume: 56 start-page: 773 year: 2017 ident: 10.1016/j.jim.2018.04.008_bb0080 article-title: The direct comparison of two interferon-gamma release assays in the tuberculosis screening of Japanese healthcare workers publication-title: Intern. Med. doi: 10.2169/internalmedicine.56.7533 – ident: 10.1016/j.jim.2018.04.008_bb0045 – year: 2017 ident: 10.1016/j.jim.2018.04.008_bb0060 – volume: 411 start-page: 50 year: 2014 ident: 10.1016/j.jim.2018.04.008_bb0070 article-title: Development of a simplified and convenient assay for cell-mediated immunity to the mumps virus publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2014.06.006 – volume: 375 start-page: 1261 year: 2016 ident: 10.1016/j.jim.2018.04.008_bb0085 article-title: Clinical practice. Influenza vaccination publication-title: N. Engl. J. Med. doi: 10.1056/NEJMcp1512870 – year: 2017 ident: 10.1016/j.jim.2018.04.008_bb0015 – year: 1997 ident: 10.1016/j.jim.2018.04.008_bb0025 – volume: 16 start-page: 650 year: 2016 ident: 10.1016/j.jim.2018.04.008_bb0040 article-title: Comparative epidemiology of influenza A and B viral infection in a subtropical region: a 7-year surveillance in Okinawa, Japan publication-title: BMC Infect. Dis. doi: 10.1186/s12879-016-1978-0 – volume: 3 start-page: 1470 year: 2007 ident: 10.1016/j.jim.2018.04.008_bb0050 article-title: Influenza virus transmission is dependent on relative humidity and temperature publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.0030151 – volume: 310 start-page: 165 year: 2016 ident: 10.1016/j.jim.2018.04.008_bb0075 article-title: Evaluation of influenza vaccine-immunogenicity in cell-mediated immunity publication-title: Cell. Immunol. doi: 10.1016/j.cellimm.2016.09.005 – volume: 21 year: 2016 ident: 10.1016/j.jim.2018.04.008_bb0020 article-title: Interim estimates of 2015/16 vaccine effectiveness against influenza A (H1N1) pdm09, Canada, February 2016 publication-title: Euro. Surveill. doi: 10.2807/1560-7917.ES.2016.21.11.30168 |
SSID | ssj0001060 |
Score | 2.2511194 |
Snippet | Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 58 |
SubjectTerms | adults antigens Cell-mediated immunity guidelines Hemagglutination inhibition IFN-γ influenza vaccination Influenza vaccine influenza vaccines interferon-gamma Neutralizing antibody |
Title | Relationship between the frequency of influenza vaccination and cell-mediated immunity |
URI | https://dx.doi.org/10.1016/j.jim.2018.04.008 https://www.ncbi.nlm.nih.gov/pubmed/29684427 https://www.proquest.com/docview/2031030054 https://www.proquest.com/docview/2153632110 |
Volume | 458 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSxxBEC5ESchFjDFxfSwdyEmYONOv6TnKomwS9BTFWzPTDzIis8u6CuvB3251z8yKoHvIcYYqaKqqq7_qrgfAjzI1uaXOJJ57l3ChXFIhME9UllpqqgwxerjQP7-Q40v--1pcr8Gor4UJaZWd7299evTW3Z_jTprH07oONb4U8bQo0Cjjg16oYOd5sPKfTy9pHhjypH3H8EDdv2zGHK-bOhSjZyp2Ow0TJt8-m97DnvEMOtuCzQ48kpN2fZ9hzTXb8KEdJ7nYho_n3UP5F7haJrn9q6ekS8YiCPaIn7XJ0wsy8aRuR5Q8luShNMgZWUjZWBIu9JNYVoKQlNSximS-2IHLs9O_o3HSjVBIDBd0ngjJqoq63EhKlUOFZdYXInSnLqxwvPA5kw4jHusrlltvQ3MppwxzucTNLSz7CuvNpHG7QGzJrVK-kIXJuDVcMZMaQQ1GuYpJwQaQ9sLTpusvHsZc3Oo-kexGo7x1kLdOuUZ5D-BoyTJtm2usIua9RvQrC9Ho_Fexfe-1p3HnBOmVjZvc3yFRnLGGmHUFDR4IkoUgeQDfWtUvV0oLqTin-d7_LWwfPoWvNvX3ANbns3t3iABnXg2jBQ9h4-TXn_HFM_3_-Mk |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7SDW16CW3apJv0oUJPBRNbL8vHEBo2TXZPSclN2HoQh-Bd0k1h--s7kuWFQrqHXm0NiBlp9I30zQzAlzo3paXOZJ57l3GhXNYgMM9UkVtqmgIxerjQn87k5Jp_vxE3W3A65MIEWmXy_b1Pj946fTlO2jxetG3I8aWIp0WFizI-6D2D7VCdSoxg--T8YjJbO2SMevKhaHgQGB43I83rrg356IWKBU9Dk8mnj6d_wc94DJ29gt2EH8lJP8XXsOW6PXjed5Rc7cGLaXorfwM_1jy323ZBEh-LIN4j_qHnT6_I3JO271Lyuya_aoOSUYTUnSXhTj-LmSWISkkbE0mWq7dwffbt6nSSpS4KmeGCLjMhWdNQVxpJqXJos8L6SoQC1ZUVjle-ZNJh0GN9w0rrbagv5ZRhrpS4v4Vl-zDq5p17B8TW3CrlK1mZglvDFTO5EdRgoKuYFGwM-aA8bVKJ8dDp4l4PXLI7jfrWQd865xr1PYava5FFX19j02A-WET_tUg0-v9NYp8H62ncPEF7defmjz9xUGyzhrB1wxg8EyQLcfIYDnrTr2dKK6k4p-Xh_03sE-xMrqaX-vJ8dnEEL8Ofngn8HkbLh0f3AfHOsvmY1vMfhtX7eg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relationship+between+the+frequency+of+influenza+vaccination+and+cell-mediated+immunity&rft.jtitle=Journal+of+immunological+methods&rft.au=Otani%2C+Naruhito&rft.au=Shima%2C+Masayuki&rft.au=Ueda%2C+Takashi&rft.au=Ichiki%2C+Kaoru&rft.date=2018-07-01&rft.eissn=1872-7905&rft.volume=458&rft.spage=58&rft_id=info:doi/10.1016%2Fj.jim.2018.04.008&rft_id=info%3Apmid%2F29684427&rft.externalDocID=29684427 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1759&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1759&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1759&client=summon |